Congenital Afibrinogenemia
A rare inherited disorder in which the body produces no functional fibrinogen, a key clotting protein, leading to a significant lifelong bleeding tendency.
- Specialist hematology review
- Fibrinogen replacement guidance
- Pregnancy & procedure planning support
- Inheritance
- Autosomal Recessive (FGA, FGB, or FGG)
- Most Common In
- Often diagnosed in infancy or early childhood
- Clinical Hallmark
- Absent Fibrinogen, Significant Bleeding Tendency
- Advanced Therapies
- Fibrinogen Concentrate, Cryoprecipitate, Prophylactic Replacement
Condition Overview
Congenital afibrinogenemia is a rare inherited bleeding disorder in which the body fails to produce fibrinogen, a protein essential for forming the final, stabilizing mesh of a blood clot. Without fibrinogen, even minor injuries can result in prolonged or excessive bleeding, and the body cannot properly stop bleeding after trauma, surgery, or childbirth.
The condition is caused by mutations affecting one of three genes (FGA, FGB, or FGG) that together encode fibrinogen. It is typically identified in infancy or early childhood, sometimes after umbilical cord bleeding at birth, though milder related forms (hypofibrinogenemia) may not be recognized until later in life.
Because fibrinogen also supports wound healing and placental function, affected individuals require careful, lifelong coordination of care โ including prophylactic fibrinogen replacement in some cases โ to manage bleeding risk during everyday life, procedures, and pregnancy.
Types and Subtypes
Congenital afibrinogenemia exists along a spectrum of inherited fibrinogen deficiency, distinguished primarily by how much functional fibrinogen, if any, is produced.
Symptoms and Signs
Symptoms reflect the body's inability to form a stable clot and can range from mild bruising to life-threatening bleeding.
Causes and Risk Factors
Congenital afibrinogenemia is caused entirely by inherited gene mutations affecting fibrinogen production; it is not caused by lifestyle or environmental factors.
Diagnosis and Investigations
Diagnosis relies on specific coagulation testing that directly measures fibrinogen, supported by genetic confirmation.
Disease Severity Classification
Congenital afibrinogenemia does not use a cancer-style staging system; severity is classified by bleeding history and fibrinogen level to guide prophylactic treatment decisions.
Standard Treatment Options
Treatment centers on replacing the missing fibrinogen, either when bleeding occurs or proactively to prevent it.
Advanced and Emerging Treatment Options
Modern fibrinogen concentrates have substantially improved the ability to manage and prevent bleeding compared with older replacement methods.
Precision Medicine
Plasma-derived fibrinogen concentrate
A purified, virally inactivated fibrinogen replacement product that allows precise dosing for both on-demand treatment and prophylaxis.
Targeted Therapy
Individualized prophylaxis regimens
Tailored long-term fibrinogen replacement schedules based on bleeding history and trough fibrinogen levels.
Gene Therapy
Investigational gene-based approaches
Early research is exploring gene therapy concepts for inherited fibrinogen disorders, though this remains experimental.
Biomarkers and Precision Medicine
Specific coagulation markers are used to confirm diagnosis, assess severity, and guide replacement therapy dosing.
When a Second Opinion May Be Important
Given the rarity and potential severity of congenital afibrinogenemia, specialist review supports safer long-term planning.
Clinical Trials and Research
Prognosis and Key Outcome Factors
With appropriate fibrinogen replacement and specialist follow-up, many people with congenital afibrinogenemia manage the condition successfully through childhood, adulthood, and pregnancy, though the risk of serious bleeding requires ongoing vigilance.
Supportive Care and Living With Congenital Afibrinogenemia
Ongoing supportive measures help reduce bleeding risk and support safe participation in everyday activities.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with congenital afibrinogenemia access specialist hematology review, second opinions on replacement therapy planning, and coordination for procedures or pregnancy management.
Get a free case reviewFrequently Asked Questions
It is a rare inherited bleeding disorder in which the body produces no functional fibrinogen, a protein essential for forming stable blood clots, leading to a significant lifelong bleeding tendency.
It is often first noticed through prolonged bleeding from the umbilical cord stump in newborns, or through easy bruising and frequent nosebleeds in young children.
Both are inherited bleeding disorders, but hemophilia involves deficiency of specific clotting factors (such as factor VIII or IX), while afibrinogenemia involves complete absence of fibrinogen itself; the two are diagnosed and treated differently.
Yes, it follows an autosomal recessive pattern, requiring a mutated gene copy from each parent for the full condition to occur.
Treatment involves replacing the missing fibrinogen using fibrinogen concentrate or cryoprecipitate, either at the time of bleeding or, for some patients, on a regular prophylactic schedule.
Yes, it increases the risk of miscarriage, placental complications, and bleeding during delivery, so pregnancy requires close coordination between hematology and obstetric specialists.
There is currently no cure for the underlying genetic defect; management relies on lifelong fibrinogen replacement and bleeding precautions.
High-contact sports and activities with significant injury risk are often discouraged, with specific recommendations individualized based on bleeding history.
Genetic counseling and testing of close relatives can clarify carrier status and is often recommended, especially when planning a pregnancy.
Yes. CancerFax can help coordinate medical report review, connect you with hematology specialists for a second opinion, and support planning for procedures, pregnancy, or replacement therapy, including cross-border coordination where needed.
Get Expert Guidance for Congenital Afibrinogenemia
Share your reports with our team to explore specialist review and bleeding management support.